Results 61 to 70 of about 57,324 (252)

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Journal of Immunology Research, 2017
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells.
Baixin Ye, Creed M. Stary, Qingping Gao, Qiongyu Wang, Zhi Zeng, Zhihong Jian, Lijuan Gu, Xiaoxing Xiong   +7 more
doaj   +1 more source

Principles of adoptive T cell cancer therapy [PDF]

Journal of Clinical Investigation, 2007
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy.
openaire   +2 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Molecular Cancer, 2023
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration
Qiaofei Liu, Jiayi Li, Huaijin Zheng, Sen Yang, Yuze Hua, Nan Huang, Jorg Kleeff, Quan Liao, Wenming Wu   +8 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Adoptive γδ T cell therapy controls cytomegalovirus infection in preclinical transplantation models

Nature Communications
γδ T cells show promise for anti-tumoral therapies but have yet to be evaluated to treat infectious diseases. In this preclinical study, we assess a Vδ1 + γδ T cell-based adoptive cell therapy, named Delta One T cells, to treat cytomegalovirus (CMV ...
Gabriel Marsères, Coline Gentil, Claire Tinevez, Maxime Courant, Anaïs Cosentino, Selma Cornillot-Clément, Victor Bigot, Vincent Pitard, Atika Zouine, Julien Izotte, Isabelle Garrigue, Valérie Prouzet-Mauleon, Béatrice Turcq, Dany Anglicheau, Edouard Forcade, Hannah Kaminski, Bruno Silva-Santos, Pierre Merville, Myriam Capone, Julie Déchanet-Merville, Lionel Couzi   +20 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Prospectives of T-cells genetic programming in adoptive immunotherapy of malignancies

Сеченовский вестник, 2016
The article reviews the literature on adoptive T-cell therapy of malignancies. Adoptive T-cell transfer allows treatment of metastatic disease on the late stages of certain tumors.
O. L. Morozova, V. V. Yakovlev, N. A. Sushentsev   +2 more
doaj  

ADOPTIVE CELL THERAPY: CURRENT ADVANCES

Южно-Российский онкологический журнал, 2020
The immune system plays an important role in the development and treatment of many cancer types. This fact determined the emergence of numerous immunotherapeutic approaches, including that of adoptive cell therapy (ACT).
T. V. Shamova, A. O. Sitkovskaya, L. N. Vashchenko, E. E. Kechedzhieva   +3 more
doaj   +1 more source